CRP and cancer: Taken together, differences in the geographic backgrounds, biological characteristics of different tumors, selection of the CRP cutoff valve, patient heterogeneity, small sample sizes, and different definitions of end points (disease-free, cancer specific survival, or overall survival) may contribute to these discrepancies.